Prenostics Test
Early Detection (Stage 0-2) - Ovarian Cancer in high-risk women
Key Facts
About Prenostics
Prenostics is pioneering a paradigm shift in oncology through its proprietary blood test designed to detect stage 0-2 cancers, a capability claimed to be years ahead of current diagnostic standards. Founded by Oxford Professor Sarah Blagden, the company leverages a novel biomarker to enable early intervention and curative treatment pathways. With an experienced leadership team blending deep scientific expertise and commercial diagnostics experience, Prenostics is initially targeting high-risk ovarian cancer and indeterminate lung nodules. The company is a private, pre-revenue entity positioned in the high-growth, high-impact field of multi-cancer early detection.
View full company profileAbout Prenostics
Prenostics is pioneering a paradigm shift in oncology through its proprietary blood test designed to detect stage 0-2 cancers, a capability claimed to be years ahead of current diagnostic standards. Founded by Oxford Professor Sarah Blagden, the company leverages a novel biomarker to enable early intervention and curative treatment pathways. With an experienced leadership team blending deep scientific expertise and commercial diagnostics experience, Prenostics is initially targeting high-risk ovarian cancer and indeterminate lung nodules. The company is a private, pre-revenue entity positioned in the high-growth, high-impact field of multi-cancer early detection.
View full company profile